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Background: Endovascular interventions for May Thurner Syndrome
(MTS) have become first line therapy, often performed in a young patient
population despite the lack of robust supportive data. This paper reports on
long term outcomes from a large series of patients treated for de-novo or
posthrombotic presentation.
Methods: A retrospective review of MTS patients stented between
2006 and 2010 at two institutions. Patients who presented with acute
iliofemoral DVT were treated with either catheter directed thrombolysis
(CDT) and/or pharmacomechanical thrombolysis (PMT) and identified as
having a venous stenosis by venogram. Patients who presented with leg pain
or swelling but no DVT and evidence of MTS on duplex were evaluated by
venography. IVUS was selectively utilized. Stenting of the iliocaval junction
was performed in all patients with a50% diameter stenosis on venogram, or
a 70% area stenosis on IVUS.
Table. Patient characteristics and procedure analysis
Stenting after PMT/CDT
(postthrombotic) N38(%)
Stenting alone (de novo
presentation) N15(%) P value
Females 23 (61%) 11 (73%) .38
Average age 52 (range, 16-80 years) 55 (range, 25-67 years) .60
Hypercoagulable state 9 (24%) 0 .04
Coronary artery
disease
6 (16%) 1 (7%) .38
Diabetes 4 (11%) 4 (27%) .14
Hyperlipidemia 13 (34%) 3 (20%) .31
Hypertension 17 (45%) 7 (47%) .90
Left side 34 (89%) 11 (73%) .14
Average preoperative
CEAP score
2.7 3.8 .05
Number of patients
wearing
compression
stockings pre-
operatively
16 (42%) 15 (100%) .01
Average stent size
(mm)
14 mm (range, 10-22) 17 mm (range, 12-22) .01
IVUS use 19 (51%) 12 (80%) .04
Stent type .01
-Balloon expandable 7 (18%) 8 (53%)
-Self expanding 31 (82%) 7 (47%)
ŒProtégé (EV3) 28 (90%) 4 (57%)
ŒWallstent (Boston
Sci)
3 (10%) 3 (43%)
Bleeding
complications
0 0 N/A
Mean length of
follow-up
15 months 11 months
Complete or partial
symptom relief
31 (89%) 15 (100%) .17
Change in CEAP
score at follow-up
0.16 (P.81) 0.27 (P.04)
Results: 51 patients with MTS underwent 53 lower extremity inter-
ventions. They were divided into two groups: postthrombotic (Group 1)
and de-novo presentation of swelling/pain but no DVT (group 2). There
were 38 extremities in group 1 and 15 extremities in group 2 (Table). Both
groups were comparable in terms of gender distribution and comorbidities,
but hypercoagulable state was more common in group 1 (P.04), and
average CEAP score on presentation was higher in group 2 (P.05).There
were left sided symptoms in 34 (89%) patients in group 1 and 10 (77%) of
group 2 (P.26). Males represent 75% of patients with right sided symp-
toms, but only 30% of patients with left sided symptoms (P.019). The
average stent size was significantly different among the groups, (P.001),
with different types used in each group. (Table). There were no procedural
complications in either group. Mean follow-up was 15 months in group 1
(range, 1-42 months) and 11 months in group 2 (1-24 months). Complete
or partial symptom relief was reported for 31 (89%) extremities in group 1
and 15 (100%) extremities in group 2 (P.17). A normal Valsalva response
was seen in all patients with a patent stent on the most recent follow up
duplex, with an overall primary patency at 3 years by lifetable analysis of 96%
(94% in group1, 100% in group 2) and secondary patency of 98%.
Conclusion: Stenting of MTS has proven to be safe, efficacious and
durable for up to 36 months in both the post thrombotic patient as well as
those treated for edema alone.
Outcomes and Predictors of Secondary Intervention for Chronic Ve-
nous Insufficiency Following Endovenous Radiofrequency Ablation
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Background: Endovenous ablation for the treatment of chronic venous
insufficiency (CVI) affords patients aminimally invasive treatment alternative to
traditional surgical procedures. Endovenous ablation is highly technically and
clinically successful such that only aminority of patientsmay require subsequent
treatment for either extensive varicosities or for veins in which ablation was
unsuccessful. The purpose of this study was to develop a predictive model to
forecast this requirement for secondary procedures despite successful primary
endovenous radiofrequency ablation (RFA) for CVI.
Methods: Subjects were identified from a University Vein Center
database and assigned to one of two groups: (1) Control: patients whose
RFA was successful as a primary standalone procedure in alleviating symp-
toms and decompressing varicosities, or (2) Reintervention: patients who
required additional treatment to correct their disease after initial RFA did
not provide a complete clinical response. For patients who had bilateral RFA,
each limb was identified independently for both the primary and secondary
procedures. Secondary procedures were defined as phlebectomy, vein strip-
ping, sapheno-femoral junction (SFJ) ligation, or radiofrequency ablation of
the same vein or additional accessory veins. Patients who were treated
exclusively with sclerotherapy as a secondary intervention were excluded.
Data was analyzed using sequential univariate and multivariate regressions
along with Chi-square goodness of fit.
Results: Of the 185 patients included in this study, 32 patients
required a secondary intervention (17.3%). Secondary procedures included
phlebectomy 53%, secondary RFA 28%, combined RFA and phlebectomy
6%, SFJ ligation 6%, and vein stripping 3%. The mean Venous Clinical
Severity Scores (VCSS) for the control and reintervention groups were 4.8
and 6.7, respectively (P.001). The overall median VCSS was 5 (range, 2 -
17). For subjects with a VCSS  5, the requirement for secondary proce-
dures was 10-fold greater. Univariate regression suggested that BMI, dia-
betes, pain, varicosities, edema, pigmentation, induration, compression, and
total VCSS contributed to the need for secondary intervention at the p.1
level. Multivariate regression modeling these covariates showed indepen-
dent predictive association between increasing total VCSS and secondary
intervention (P.0001), and an inverse association between increasing BMI
and a decreased risk of reintervention following RFA (P.008).
Conclusions: Secondary procedures were required only in 17% of
patients following RFA, so for most, a staged approach to any secondary
procedures may be appropriate. With the knowledge gained from this study,
clinicians may be able to better individualize patient treatment by identifying
those at up front greater risk of requiring a secondary procedure. For this
subset, providing comprehensive treatment, such as a combination of RFA
with SFJ ligation or phlebectomy, could mitigate the risks of additional
surgical procedures.
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Background: Although duplex ultrasound is the gold standard for the
diagnosis of lower extremity deep venous thrombosis(LE-DVT), imaging is
not always available. The use of D-dimer can exclude(high sensitivity), but
not rule in(low specificity) LE-DVT. In a derivation cohort, we previously
demonstrated that soluble P-selectin(sPsel) with Wells score, establishes the
diagnosis of LE-DVT with specificity of 96% and positive predictive val-
ue(PPV) of 100%. In order to validate our previous results, we applied the
model from our derivation cohort to a separate but similar validation cohort,
differing by allowing inclusion of patients on immunosuppression or pro-
phylactic anticoagulation.
Methods: Demographics, clinical data, D-dimer, sPsel, C-reactive
protein(CRP), ADAMTS-13, and von Willebrand factor(vWF) levels were
prospectively collected in 160 patients presenting to our ultrasound lab with
an anticipated diagnosis of LE-DVT. Continuous (Students t-test) and
categorical (Chi squared test) variables among patients with ultrasound
confirmed LE-DVT were compared to patients without LE-DVT. The
diagnostic sensitivity, specificity, PPV and negative predictive value(NPV)
was then calculated using cut points from our derivation cohort to rule in
LE-DVT (sPsel 90ng/mL or D-dimer 500ng/mL and Wells score2)
as well as exclude LE-DVT(sPsel60ng/mL or D-dimer500ng/mL and
Wells score 2).
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